Antibody molecules having specificity for human IL-1β

Details Antibody molecules having specificity for human IL-1β Antibody molecules having specificity for human IL-1β

2004-02-06

2009-10-27

Blanchard, David J. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C424S133100, C424S141100, C424S145100, C435S069600, C435S070210, C530S387300, C530S388100, C530S391100

Reexamination Certificate

active

07608694

ABSTRACT:
The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.

REFERENCES:
patent: 4935343 (1990-06-01), Allison et al.
patent: 5474899 (1995-12-01), Lisi
patent: 5681933 (1997-10-01), Auron et al.
patent: 2003/0026806 (2003-02-01), Witte et al.
patent: 0 392 745 (1994-11-01), None
patent: 0 813 423 (2002-07-01), None
patent: 0 948 544 (2003-05-01), None
patent: 129105 (1919-07-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 89/00195 (1989-01-01), None
patent: WO 89/01476 (1989-03-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/22583 (1992-12-01), None
patent: WO 93/06231 (1993-04-01), None
patent: WO 95/01997 (1995-01-01), None
patent: WO 98/20734 (1998-05-01), None
patent: WO 99/15549 (1999-04-01), None
patent: WO01/53353 (2001-07-01), None
patent: WO02/16436 (2002-02-01), None
patent: WO03/010282 (2003-02-01), None
patent: WO2004/072116 (2004-08-01), None
Fundamental Immunology, 3rd Edition, William E. Paul, M.D., ed., pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Colman P. M. Research in Immunology, 145:33-36, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Chapman, A.P., “PEGylated antibodies and antibody fragments for improved therapy: a review,”Advanced Drug Delivery Reviews, 2002, 54, 531-545.
Chapman, A.P., et al., “Therapeutic antibody fragments with prolonged in vivo half-lives,”Nature Biotechnology, 1999, 17, 780-783.
Chothia, C., et al., “Canonical structures fro the hypervariable regions of immunoglobulins,”J. Mol. Biol., 1987, 196, 901-917.
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution,”Nature, 1998, 391, 288-291.
Davies, J., et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,”Immunotechnology, 1996, 2, 169-179.
Dinarello, C.A., “Biologic basis for interleukin-1 in disease,”Blood, 1996, 87(6), 2095-2147.
Hieter, P.A., et al., “Evolution of human immunoglobulin κ J region genes,”J. Biol. Chem., 1982, 257(3), 1516-1522.
Low, N.M., et al., “Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain,”J. Mol. Biol., 1996, 260, 359-368.
Marks, J.D., et al., “By-passing immunization: building high affinity human antibodies by chain shuffling,”Bio/Technology, 1992, 10, 779-783.
Movva, N.R., et al., “Amino acid sequence of the signal peptide of ompA protein, a major outer membrane protein ofEscherichia coli,”J. Biol. Chem., 1980, 255(1), 27-29.
Patten, P.A., et al., “Applications of DNA shuffling to pharmaceuticals and vaccines,”Curr. Opin. Biotechnol., 1997, 8, 724-733.
Ravetch, J.V., et al., “Structure of the human immunoglobulin μ locus: characterization of embryonic and rearranged J and D genes,”Cell, 1981, 27, 583-591.
Reichmann, L., et al., “Reshaping human antibodies for therapy,”Nature, 1998, 332, 323-324.
Thompson, J., et al., “Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,”J. Mol. Biol., 1996, 256, 77-88.
Vaughan, T.J., et al., “Human antibodies by design,”Nature Biotechnology, 1998, 16, 535-539.
Wada, K.-N., et al., “Codon usage tabulated from the GenBank genetic sequence data,”Nucl. Acids Res., 1991, 19, 1981-1986.
Yang, W.-P., et al., “CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range,”J. Mol. Biol., 1995, 254, 392-403.

Affiliated with

Also associated with

Rating

Antibody molecules having specificity for human IL-1β does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody molecules having specificity for human IL-1β, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody molecules having specificity for human IL-1β will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4134089